Table 1

Relationship of age, race, screening history, and tumor characteristics to type of HRT regimen among women diagnosed with breast cancer ages 50–64 years

VariableUse of pill or patch HRTa
All women with breast cancer (N = 2346)Never used HRT (N = 935)Used ERTb (N = 635c)Used S-CHRTd (N = 381c)Used C-CHRTe (N = 385c)
N (%)N (%)N (%)N (%)N (%)
Age at diagnosis (yrs)
 50–54844 (36.0)387 (41.3)176 (27.7)123 (32.3)101 (26.2)
 55–59770 (32.8)261 (27.9)233 (36.7)139 (36.5)150 (39.0)
 60–64732 (31.2)287 (30.7)226 (35.6)119 (31.2)134 (34.1)
Pf<0.0010.002<0.001
Race
 White1535 (65.4)470 (50.3)447 (70.4)332 (87.1)338 (87.8)
 Black811 (34.6)465 (49.7)188 (29.6)49 (12.9)47 (12.2)
Pf<0.001<0.001<0.001
Screening mammogram in 2 yrs before ref.
 No558 (23.8)329 (35.2)102 (16.1)35 (9.2)44 (11.4)
 Yes1788 (76.2)606 (64.8)533 (83.9)346 (90.8)341 (88.6)
Pf<0.001<0.001<0.001
Histology
 Ductal1722 (73.4)712 (76.1)462 (72.8)270 (70.9)272 (70.6)
 Any lobular331 (14.1)113 (12.1)92 (14.5)63 (16.5)79 (20.5)
 All other293 (12.5)110 (11.8)81 (12.8)48 (12.6)34 (8.8)
Tumor size
 <2 cm1316 (59.1)464 (53.0)387 (63.3)240 (65.9)252 (67.0)
 2 to <5 cm733 (32.9)317 (36.2)184 (30.1)104 (28.6)106 (28.2)
 5+ cm177 (8.0)94 (10.7)40 (6.5)20 (5.5)18 (4.8)
 Missing1206024179
Stage
 Local1492 (64.3)537 (58.1)433 (68.8)267 (70.6)262 (68.8)
 Regional/Dist830 (35.7)387 (41.9)196 (31.2)111 (29.4)119 (31.3)
 Missing2411634
ER/PR status
 ER+1470 (72.9)524 (67.8)411 (73.0)262 (76.8)286 (82.7)
 ER−547 (27.1)249 (32.2)152 (27.0)79 (23.2)60 (17.3)
 Missing329162724039
 PR+1216 (63.8)431 (59.0)338 (62.6)213 (64.7)250 (76.9)
 PR−690 (36.2)299 (41.0)202 (37.4)116 (35.3)75 (23.1)
 Missing440205955260
 ER+/PR+1136 (59.9)396 (54.5)319 (59.4)196 (59.8)235 (73.0)
 ER+/PR−233 (12.3)92 (12.7)71 (13.2)54 (16.5)29 (9.0)
 ER−/PR+74 (3.9)32 (4.4)19 (3.5)16 (4.9)13 (4.0)
 ER−/PR−452 (23.9)206 (28.4)128 (23.8)62 (18.9)45 (14.0)
 Missing451209985363
  • a Excludes women who use HRT for <6 months.

  • b ERT, unopposed estrogen.

  • c The sum of users in each category does not equal the total number of HRT users because some women used more than one regimen.

  • d S-CHRT, sequential estrogen plus progestin use (5–24 days/month).

  • e C-CHRT, continuous combined estrogen plus progestin use (25+ days/month).

  • f P (χ2 test) for relationship of variable to HRT regimen.